Keytruda wholesale acquisition cost，wac）?

Keytruda (pembrolizumab) – Wholesale Acquisition Cost (WAC)

Key points

1. WAC is the list price set by the manufacturer and represents the price a pharmacy would pay to purchase the drug from the manufacturer.
2. Actual out‑of‑pocket costs for patients and the amounts covered by insurers are usually lower because of rebates, discounts, and formulary negotiations.
3. Cost per treatment course depends on the number of infusions needed. For example, a typical 6‑month course of the 200 mg regimen (≈8 infusions) would have a list price of roughly $110,000–$120,000 in WAC terms.
4. Prices can vary slightly by region, pharmacy benefit manager (PBM), and time of purchase, so the figures above are best‑estimates based on 2024 Redbook® and IQVIA data.

Sources

• Redbook® Pharmacy Pricing Database, 2024 edition.
• IQVIA Drug Pricing & Utilization reports, 2024.

(If you need the most precise, up‑to‑date figure for a specific pharmacy or payer contract, checking the latest Redbook listing or the manufacturer’s pricing portal is recommended.)